lisdexamfetamine-dimesylate and Pain

The increased use of opioid pain medication has been mirrored by the increased misuse and abuse of these drugs. As part of a multidisciplinary approach to this epidemic, pharmaceutical companies, with the encouragement of the Food and Drug Administration, have increased the development of abuse-deterrent formulations. While all have the goal of treating pain while mitigating misuse and abuse, there are different technologies utilized to impart the abuse-deterrent properties. The goal of this paper is to review the basis of abuse-deterrent formulations, the different types and approaches of some of the abuse-deterrent products, and their current regulatory status in the USA.

Topics: Analgesics, Opioid; Buprenorphine; Chemistry, Pharmaceutical; Dextroamphetamine; Humans; Lisdexamfetamine Dimesylate; Morphine; Naltrexone; Opioid-Related Disorders; Pain; Prescription Drug Misuse; United States; United States Food and Drug Administration